Arecor Therapeutics plc (AIM: AREC)

Market Cap	22.09M
Revenue (ttm)	4.90M
Net Income (ttm)	-8.67M
Shares Out	37.76M
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,712
Average Volume	11,102
Open	60.00
Previous Close	58.50
Day's Range	57.50 - 60.00
52-Week Range	0.55 - 170.00
Beta	-0.27
RSI	17.67
Earnings Date	Dec 27, 2024

About Arecor Therapeutics

Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications ion the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 50
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AREC

Financial Performance

In 2023, Arecor Therapeutics's revenue was 4.57 million, an increase of 90.30% compared to the previous year's 2.40 million. Losses were -8.55 million, -7.62% less than in 2022.